<DOC>
	<DOCNO>NCT01810653</DOCNO>
	<brief_summary>The study design combine long-term safety dose range determination objective . The first 8 week study primarily intend dose range determination , later visit use comparison long-term safety group .</brief_summary>
	<brief_title>A Study Compare Effect Transipeg 2.95 g Forlax Junior 4 g Children With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Childhood functional constipation 6 month &lt; 16 year age Male female For female childbearing potential ( menarche ) : negative pregnancy test Moderately severe severe constipation , define stool frequency &lt; 3 stools/week Informed consent sign parent ( ) legal acceptable representative ( ) , sufficient oral write information enter study , document investigator Case Report Form Functional nonretentive fecal incontinence Known metabolic endocrine disorder ( s.a. hypothyroidism ) Neurologic disorder ( s.a. spina bifida spinal cord anomaly ) Hirschsprung 's disease ( congenital megacolon ) Anal anomaly Gastrointestinal surgery Drug induce constipation Mental retardation Cerebral palsy Treatment laxatives Drugs influence gastrointestinal function ( e.g. , cisapride , erythromicin , imodium ) Prior bowel surgery , except appendectomy Earlier participation trial Concurrent participation clinical trial Participation clinical study 6 month prior inclusion Any use Macrogol within 2 month prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Macrogol</keyword>
</DOC>